WuXi BioLogics wins Adagene antibody therapeutics contract

By Flora Southey contact

- Last updated on GMT

WuXi BioLogics will develop and manufacture Adagene’s antibody therapeutics for the Chinese market before expanding globally.

The strategic collaboration will see the Hong-Kong-headquartered contract development and manufacturing organisation (CDMO) make antigen-focused therapies.

“This collaboration is expected to introduce the world-class life-saving biologics to the Chinese market, and then benefit patients around the world,” ​said WuXi BioLogics CEO Chris Chen in a statement​.

The antibody therapeutics will be developed at WuXi BioLogics’ biologics development facility​ in Shanghai, and made at its manufacturing site​ in WuXi City, spokesperson Lia Jia told us.

WuXi BioLogics’ manufacturing plant – located 100km west of Shanghai – consists of two 1,000L single-use bioreactors, and 14 2,000L fed-batch cell culture disposable vessles supplied​ by vendor Thermo Fisher.

Three months ago the CDMO announced​ it had initiated current good manufacturing practice (cGMP) production at the site.

At the time, WuXi BioLogics told told Biopharma-Reporter the facility’s 30,000L capacity was already “mostly filled.”

Related news

Show more

Related products

show more

Discover the world of upstream bioprocessing

Discover the world of upstream bioprocessing

Eppendorf Bioprocess Solutions | 07-Sep-2022 | Technical / White Paper

A must-read for all bioprocess scientists: This bundle of four ebooks created by Eppendorf guides you through the world of upstream bioprocessing.

dPCR Case Study

dPCR Case Study

CellCarta | 08-Aug-2022 | Case Study

Streamline your adoptive cell therapy program with digital PCR. Our team has a unique expertise in digital and quantitative PCR to support you in ensuring...

The Reagents Behind Much of Molecular Biology

The Reagents Behind Much of Molecular Biology

Thermo Fisher Scientific | 25-Jul-2022 | Case Study

The ability to amplify, modify and fabricate DNA is fundamental to modern molecular biology. Why do so many researchers take their constituent parts for...

Microsampling in Early Phase Drug Development

Microsampling in Early Phase Drug Development

Altasciences | 10-May-2022 | Technical / White Paper

Microsampling significantly lessens the volume of blood and plasma/serum that is collected and analyzed to determine circulating concentrations of therapeutic...

Related suppliers

Follow us


View more